PMID- 18076367
OWN - NLM
STAT- MEDLINE
DCOM- 20080411
LR  - 20191110
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
VI  - 12
IP  - 1
DP  - 2008 Jan
TI  - Targeting ischemic brain injury with intravenous immunoglobulin.
PG  - 19-29
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a therapeutic modality approved 
      for the treatment of autoimmune disorders. OBJECTIVE: This review discusses how 
      IVIG can prevent brain damage following ischemic stroke and discuss the potential 
      mechanisms of action. METHODS: Medline and the world wide web were searched and 
      the relevant literature was classified under the following categories: IVIG, IVIG 
      mechanism of action, and ischemic stroke injury mechanisms. RESULTS/CONCLUSION: 
      Brain ischemia induces an inflammatory response that contributes to neuronal cell 
      death. Because of its ability to block multiple molecular events, IVIG may have 
      particularly strong neuroprotective action against ischemic brain injury. In 
      light of the extensive clinical experience with IVIG for other indications, 
      development of clinical trials to evaluate the use of IVIG in human stroke 
      patients are warranted.
FAU - Arumugam, Thiruma V
AU  - Arumugam TV
AD  - Texas Tech University Health Sciences Center, Department of Pharmaceutical 
      Sciences, School of Pharmacy, Amarillo, Texas 79106, USA. 
      thiruma.arumugam@ttuhsc.edu
FAU - Selvaraj, Pradeep K
AU  - Selvaraj PK
FAU - Woodruff, Trent M
AU  - Woodruff TM
FAU - Mattson, Mark P
AU  - Mattson MP
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Brain Injuries/drug therapy/metabolism
MH  - Brain Ischemia/*drug therapy/metabolism
MH  - Drug Delivery Systems/*methods/trends
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Signal Transduction/drug effects/physiology
RF  - 114
EDAT- 2007/12/14 09:00
MHDA- 2008/04/12 09:00
CRDT- 2007/12/14 09:00
PHST- 2007/12/14 09:00 [pubmed]
PHST- 2008/04/12 09:00 [medline]
PHST- 2007/12/14 09:00 [entrez]
AID - 10.1517/14728222.12.1.19 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2008 Jan;12(1):19-29. doi: 10.1517/14728222.12.1.19.